AC Immune SA Beta
Cos'è Beta di AC Immune SA?
Beta di AC Immune SA è 0.82
Qual è la definizione di Beta?
BETA indica se una azione è più o meno volatile rispetto al mercato nel suo complesso. Un beta inferiore a 1 indica che la azione è meno volatile rispetto al mercato, mentre un beta più di 1 indica che la azione è più volatile. La volatilità è misurata come la fluttuazione del prezzo attorno alla media.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta di aziende nel Health Care settore su NASDAQ rispetto a AC Immune SA
Cosa fa AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Aziende con beta simili a AC Immune SA
- Punjab National Bank ha Beta di 0.82
- ALSO AG ha Beta di 0.82
- Pantronics ha Beta di 0.82
- RIWI ha Beta di 0.82
- SFL Ltd ha Beta di 0.82
- Tantech Ltd ha Beta di 0.82
- AC Immune SA ha Beta di 0.82
- Greenlam Industries ha Beta di 0.82
- POCL Enterprises ha Beta di 0.82
- Tech Mahindra ha Beta di 0.82
- Southern Arc Minerals ha Beta di 0.82
- TSS ha Beta di 0.82
- LifeTech Scientific ha Beta di 0.82